Clinical Trial Update: EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating switched therapy in pulmonary arterial hypertension; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Orenitram (treprostinil)
• Remodulin (treprostinil)

Snippet

Sponsor: United Therapeutics | Conditions: Pulmonary Arterial Hypertension | Phase 4 | Status: COMPLETED | Results posted: 2023-08-07